A Pilot Study on Tocilizumab in Very-Late-Onset Myasthenia Gravis

References

• Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–490. doi:10.1016/S1474-4422(09)70063-8
   PubMed Web of Science ®Google Scholar
• Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021;20(1):102712. doi:10.1016/j.autrev.2020.102712
   PubMed Web of Science ®Google Scholar
• Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570–2581. doi:10.1056/NEJMra1602678
   PubMed Web of Science ®Google Scholar
• Barnett C, Bril V. New insights into very-late-onset myasthenia gravis. Nat Rev Neuro. 2020;16(6):299–300. doi:10.1038/s41582-020-0345-3
   PubMed Web of Science ®Google Scholar
• Cortés-Vicente E, Álvarez-velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94(11):e1171–e1180. doi:10.1212/WNL.0000000000008903
   PubMed Web of Science ®Google Scholar
• Alkhawajah NM, Oger J. Treatment of myasthenia gravis in the aged. Drugs Aging. 2015;32(9):689–697. doi:10.1007/s40266-015-0297-2
   PubMed Web of Science ®Google Scholar
• Vijayan J, Menon D, Barnett C, Katzberg H, Lovblom LE, Bril V. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve. 2021;64(4):462–466. doi:10.1002/mus.27369
   PubMed Web of Science ®Google Scholar
• Casetta I, Groppo E, De Gennaro R, et al. Myasthenia gravis: a changing pattern of incidence. J Neurol. 2010;257(12):2015–2019. doi:10.1007/s00415-010-5651-z
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yuan X, Zhang C, et al. Efficacy and safety of Tacrolimus Therapy for a single Chinese Cohort with Very-Late-Onset Myasthenia Gravis. Front Neurol. 2022;13:843523. doi:10.3389/fneur.2022.843523
   PubMed Web of Science ®Google Scholar
• Uzawa A, Akamine H, Kojima Y, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol. 2021;358:577634. doi:10.1016/j.jneuroim.2021.577634
   PubMed Web of Science ®Google Scholar
• Uzawa A, Kuwabara S, Suzuki S, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366–374. doi:10.1111/cei.13546
   PubMed Web of Science ®Google Scholar
• Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun. 2011;36(2):135–141. doi:10.1016/j.jaut.2010.12.001
   PubMed Web of Science ®Google Scholar
• Deng C, Goluszko E, Tüzün E, Yang H, Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol. 2002;169(2):1077–1083. doi:10.4049/jimmunol.169.2.1077
   PubMed Web of Science ®Google Scholar
• Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–1988. doi:10.1080/21645515.2017.1316909
   PubMed Web of Science ®Google Scholar
• Venkiteshwaran A. Tocilizumab. MAbs. 2009;1(5):432–438. doi:10.4161/mabs.1.5.9497
   PubMed Web of Science ®Google Scholar
• Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099–3108. doi:10.1016/j.jacc.2019.10.038
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(8):a028456. doi:10.1101/cshperspect.a028456
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al.; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, Phase 2 trial. Lancet Neurol. 2020;19(5):391–401. doi:10.1016/S1474-4422(20)30070-3
   PubMed Web of Science ®Google Scholar
• Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord. 2017;27(6):565–568. doi:10.1016/j.nmd.2017.03.007
   PubMed Web of Science ®Google Scholar
• Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: association of British Neurologists’ management guidelines. Pract Neurol. 2015;15(3):199–206. doi:10.1136/practneurol-2015-001126
   PubMedGoogle Scholar
• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–425. doi:10.1212/WNL.0000000000002790
   PubMed Web of Science ®Google Scholar
• Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of Myasthenia gravis. J Clin Med. 2022;11(6):1597. doi:10.3390/jcm11061597
   PubMed Web of Science ®Google Scholar
• Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392–395. doi:10.1136/jnnp-2019-322606
   PubMed Web of Science ®Google Scholar
• Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693–699. doi:10.1002/mus.26689
   PubMed Web of Science ®Google Scholar
• Kassardjian CD, Widdifield J, Paterson JM, et al. Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol. 2020;27(4):702–708. doi:10.1111/ene.14153
   PubMed Web of Science ®Google Scholar
• Muppidi S, Guptill JT, Jacob S, et al. COVID-19–associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020;19(12):970–971. doi:10.1016/S1474-4422(20)30413-0
   PubMed Web of Science ®Google Scholar
• Jakubíková M, Týblová M, Tesař A, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418–3425. doi:10.1111/ene.14951
   PubMed Web of Science ®Google Scholar
• Roy B, Kovvuru S, Nalleballe K, Onteddu SR, Nowak RJ. Electronic health record–derived impact of COVID-19 on myasthenia gravis. J Neurol Sci. 2021;423:117362. doi:10.1016/j.jns.2021.117362
   PubMed Web of Science ®Google Scholar
• Lupica A, Di Stefano V, Iacono S, et al. Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: data from an Italian Cohort. Neurol Int. 2022;14(2):406–416. doi:10.3390/neurolint14020033
   PubMed Web of Science ®Google Scholar
• Alcantara M, Koh M, Park AL, Bril V, Barnett C. Outcomes of COVID-19 infection and vaccination among individuals with Myasthenia Gravis. JAMA Netw Open. 2023;6(4):e239834. doi:10.1001/jamanetworkopen.2023.9834
   PubMed Web of Science ®Google Scholar